ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31

Zomedica Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.08−0.00 (-0.55%)

Close on Oct 19, 2026

Market cap: $77.40M
P/E (TTM): –
Dividend yield: –

Zomedica Corp. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Depreciation & Amortization	–	–	–	–	–	0.31	0.28	0.20	0.09	0.04
Stock-Based Compensation	2.47	2.78	6.26	7.89	7.09	1.66	2.54	0.01	0.85	1.47
Deferred Income Taxes	-0.43	-0.68	-1.49	-2.54	–	–	–	–	–	–
Change in Accounts Receivable	-0.59	-1.23	-0.62	-0.28	-0.05	0	-0.01	-0.03	-0.01	-0.02
Change in Inventory	-0.55	-0.21	-1.06	-4.01	-2.77	–	–	–	–	–
Change in Accounts Payable	-0.09	-0.20	0.38	3.45	1.41	-0.84	-0.29	1.55	0.09	0.55
Change in Unearned Revenue	0.05	0.02	0.14	0.05	0.01	0	–	–	–	–
Operating Cash Flow	-18	-24	-16	-12	-14	-16	-16	-11	-7.09	-4.56
Capital Expenditures	-0.57	-5.21	-11	-0.79	-0.15	-0.01	-0.16	-0.63	-0.17	-0.23
Acquisitions	–	–	-24	-24	-71	–	–	–	–	–
Purchase of Investments	–	–	–	-128	–	–	–	–	–	–
Investing Cash Flow	20	18	1.58	-156	-72	1.01	-0.69	-0.62	-0.17	-0.24
Stock Issued	–	–	–	–	200	56	3.00	8.28	6.57	4.76
Financing Cash Flow	–	-0.07	–	0.01	219	77	15	10	7.49	4.79
Foreign Exchange Rate Adjustments	0.07	-0.09	-0.05	-0.06	0.00	–	–	–	–	–
Net Change in Cash	–	–	–	–	133	61	-1.43	-1.51	0.22	-0.02
Free Cash Flow	-18	-29	-27	-12	-14	-16	-16	-12	-7.26	-4.79
Income Taxes Paid	0.15	–	–	–	–	–	–	–	–	–
Interest Paid	–	–	–	–	0	0.00	0.02	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 65.4%
Operating margin: -56.3%
Net margin: -51.4%
Return on equity, FY2025: -52.6%

Financial strength

Current ratio: 6.43
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 79.9%

Valuation

P/E ratio: –
Price to sales: 2.10
Price to book: 0.72
Dividend yield: –